FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
News|Articles|July 16, 2024
Slideshow: Pharmacists Report Burnout is a Major Driver of Understaffing in Pharmacy Times Survey
On a scale from 1 to 10, respondents rated their feelings of burnout an average of 7.25 in the second annual Pharmacy Times Burnout and Mental Health Survey.
Advertisement
Advertisement
Burnout has become a defining challenge in health care—and specifically pharmacy—in recent years. Driven in part by the COVID-19 pandemic, levels of mental health issues have skyrocketed among pharmacists in recent years, as they deal with growing demands and fewer resources.1
Related to this article
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Advertisement
Advertisement